Emistat 8 MG


Emistat 8 MG


Stock Status:

In Stock

  • *Upload Prescription

    • (max file size 80 MB)



Emistat 8 could be a
 serotonin subtype 3 (5-HT3) receptor opponent indicated:Prevention of queasiness and spewing related with starting and rehash courses of emetogenic cancer chemotherapy.

Prevention and treatment of post-operative queasiness and vomiting.

Prevention of radiotherapy-induced queasiness and spewing.



Emistat 8 could be a
 powerfulprofoundly specific 5HT3 receptor-antagonist. Its exact mode of activity within the control of sickness and heaving isn’t known. Chemotherapeutic specialists and radiotherapy may cause discharge of 5HT within the little digestive tract starting a spewing reflex by enacting vagal afferents through 5HT3 receptors. Ondansetron blocks the start of this reflex. Enactment of vagal afferents may moreover cause a discharge of 5HT within the zone postrema, found on the floor of the fourth ventricle, and this may moreover advance emesis through a central componentIn this way, the impact of ondansetron within the administration of the sickness and spewing actuated by cytotoxic chemotherapy and radiotherapy is likely due to enmity of 5HT3 receptors on neurons found both within the fringe and central apprehensive framework. The instruments of activity in post-operative queasiness and heaving are not known but there may be common pathways with cytotoxic actuated sickness and heaving.


Dosage & Administration

Chemotherapy-Induced Queasiness and Vomiting-
Adults, Pediatric patients (6 months to 18 years): 

  • 8 mg tablet/orodispersible tablet: Three 0.15 mg/kg measurements, up to a most extreme of 16 mg per dose.
  • 4 mg orodispersible tablet: Three 0.15 mg/kg measurements, up to a greatest of 16 mg per dose.
  • Injection: Three 0.15 mg/kg dosages, up to a most extreme of 16 mg per dosageimbued intravenously over 15 minutes.

Radiotherapy-Induced Sickness and Vomiting-

  • 8 mg tablet/orodispersible tablet: Starting Measurements: 8 mg orally 1 to 2 hours some time recently radiotherapy. Post Radiotherapy: 8 mg orally each 8 hours for up to 5 days after a course of treatment.
  • 4 mg orodispersible tablet: Three 0.15 mg/kg measurements, up to a greatest of 16 mg per dose.
  • Injection: Three 0.15 mg/kg dosages, up to a greatest of 16 mg per dosageimplanted intravenously over 15 minutes.

Postoperative Queasiness and Vomiting-

  • 8 mg tablet/orodispersible tablet: 16 mg given as two 8 mg tablets
  • 4 mg orodispersible tablet: 16 mg
  • Injection: 4 mg

Pediatrics (>40 kg): Infusion: 4 mg

Pediatrics (40 kg): Infusion: 0.1 mg/kg



The potential for clinically noteworthy sedate intuitive with Ondansetron shows up to be moo.



Contraindicated in patients known to have extreme touchiness to the medicate or any of its components. Concomitant utilize of apomorphine.


Side Effects

The most common antagonistic responses in chemotherapy-induced sickness and heaving (rate 7%) are diarrhea, headache and fever. The foremost common antagonistic responses in postoperative queasiness and spewing in grown-ups is cerebral pain (rate 10%), and in pediatric patients matured 1 to 24 months is loose bowels (rate 2%).


Pregnancy & Lactation

Pregnancy Category B. Ondansetron is excreted within the breast milk of rats. It isn’t known whether ondansetron is excreted in human drainSince numerous drugs are excreted in human drain, caution ought to be worked out when ondansetron is managed to a nursing lady.


Precautions & Warnings

Touchiness responsescounting anaphylaxis and bronchospasm, have been detailed with or without known touchiness to other particular 5-HT3 receptor enemies. QT prolongation happens in a dose-dependent way.

Therapeutic Class

Anti-emetic drugs


Storage Conditions

Store at temperature not surpassing 30ºC in a dry putSecure from light and dampness.


Pharmaceutical Name

Healthcare Pharmaceuticals Ltd